Off-Label Prescribing for GLP-1s: What It Means and Why It's Legal
A large portion of GLP-1 prescriptions are off-label. Here's what off-label means in law and practice, what the most common off-label GLP-1 uses are, and why insurance may deny coverage.
A large portion of GLP-1 prescriptions written today are technically "off-label" — meaning the specific drug, dose, or indication isn't listed in the FDA-approved prescribing label. This confuses patients and sometimes gets cited to deny coverage. Here's what off-label actually means and why it's entirely legal and common.
What "off-label" means (and doesn't mean)
FDA approval applies to a specific drug, at a specific dose, for a specific indication. Off-label use means prescribing outside those parameters — a different dose, a different indication, or a different population than the approved label. Off-label prescribing is legal for licensed physicians in all 50 states; it's the standard of care in many specialties.
Very. Semaglutide 0.5–2mg (Ozempic, the T2D dose range) prescribed to a non-diabetic patient for weight loss is off-label — Wegovy 2.4mg is the obesity-approved dose. Oral semaglutide (Rybelsus) for obesity is off-label. Low-dose oral minoxidil is another widely used off-label drug. Off-label = outside the label, not outside accepted medical practice.
Common off-label GLP-1 uses in 2026
| Drug | Approved indication | Common off-label use |
|---|---|---|
| Semaglutide (Ozempic 0.5-2mg) | Type 2 diabetes | Weight loss at T2D doses in non-diabetic patients |
| Semaglutide (Rybelsus, oral) | Type 2 diabetes | Weight loss in non-diabetic patients |
| Tirzepatide (Mounjaro) | Type 2 diabetes | Weight loss in non-diabetic patients (Zepbound now approved for obesity) |
| Semaglutide 2.4mg (Wegovy) | Obesity (BMI ≥30 or ≥27 + comorbidity) | Lower BMI patients with metabolic disease, addiction/craving management |
Why insurance may not cover off-label prescriptions
Insurers are not required to cover off-label prescribing, even when it's medically appropriate. A plan that covers Wegovy (BMI ≥30 obesity) may deny Ozempic prescribed off-label for weight loss in a non-diabetic patient — even though it's the same molecule. If your plan covers only labeled indications, you may need the exact FDA-approved drug at the approved dose for your indication.
Compounded GLP-1s and off-label
Compounded semaglutide and tirzepatide are off-label by definition — compounded drugs don't have FDA approval for any indication. They're prescribed under the medical judgment of the licensed prescriber. This is legal and widely practiced, though the FDA's proposed 503B compounding guidance (comment period closed June 2026) may affect availability of large-scale compounded supply.
Verified telehealth providers
Compounded semaglutide — prescriber discretion on dosing, flexible titration.
Paid link Get started →Off-label GLP-1 programs including metabolic and longevity indications.
Paid link Get started →Telehealth GLP-1 consult — licensed prescriber review for your specific situation.
Paid link Get started →